Eagle Boston Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Eagle Boston Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$377K	Buy	+11,411	New	+$391K	0.43%	88

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

Eagle Boston Investment Management's SUPN Position: Q2 2019 in Review

Eagle Boston Investment Management opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2019: 11,411 shares worth $377K. The stake represents 0.43% of the portfolio and ranks #88 among its holdings.

272 funds tracked by Wall St. Rank hold SUPN as of Q2 2019.

Eagle Boston Investment Management held 11,411 shares of Supernus Pharmaceuticals worth $377K as of Q2 2019.
Supernus Pharmaceuticals was a new Eagle Boston Investment Management position in Q2 2019.
Supernus Pharmaceuticals made up 0.43% of Eagle Boston Investment Management's portfolio in Q2 2019, its #88 holding.
272 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2019.

Based on Eagle Boston Investment Management's 13F filing for Q2 2019, filed 5 Aug 2019.